Localization of experimental brain tumors in MRI by gadolinium porphyrin

Area of Science:

• Neuroimaging
• Oncology
• Radiology

Background:

• Accurate detection and characterization of brain tumors like F98 glioma are crucial for effective treatment.
• Magnetic Resonance Imaging (MRI) is a primary modality for brain tumor diagnosis, but contrast enhancement is often necessary.
• Developing novel contrast agents that selectively target tumors can improve diagnostic accuracy.

Purpose of the Study:

• To evaluate the efficacy of a synthetic gadolinium-porphyrin complex, GdTPPS, as an MRI contrast agent for F98 gliomas in a rat model.
• To assess the impact of GdTPPS on T1 and T2 relaxation times in both tumor and normal brain tissues.
• To determine the resulting changes in MRI signal intensity for gliomas under T1- and T2-weighted imaging.

Main Methods:

• Intraperitoneal injection of GdTPPS in rats bearing F98 gliomas.
• Acquisition of T2-weighted MRI scans (TE 130 ms, TR 3 s) to assess contrast enhancement.
• Measurement of T1 and T2 relaxation times in gliomas and normal brain tissues (cortex, corpus callosum, temporal muscle, ventricles) before and after GdTPPS administration.

Main Results:

• GdTPPS significantly enhanced the contrast between edema and F98 glioma in T2-weighted MRI.
• T1 relaxation time of F98 gliomas was selectively shortened by approximately 50% (1339 ms to 628 ms).
• T2 relaxation time of F98 gliomas was shortened by approximately 35% (86 ms to 57 ms), while normal tissues remained unaltered.
• GdTPPS application resulted in hyperintensity in T1-weighted MRI and hypointensity in T2-weighted MRI for F98 gliomas.

Conclusions:

• The synthetic gadolinium-porphyrin complex, GdTPPS, effectively enhances MRI contrast for F98 gliomas.
• GdTPPS selectively shortens T1 and T2 relaxation times in gliomas without affecting normal brain tissues.
• This selective alteration leads to improved visualization of F98 gliomas as hyperintense on T1-weighted and hypointense on T2-weighted MRI.